EXON 14 SKIPPING MUTATION 首页/癌基因/MET/ EXON 14 SKIPPING MUTATION MET基因编码的蛋白为肝细胞生长因子受体HGFR,具有酪氨酸激酶活性,与多种癌基因产物和调节蛋白相关,参与细胞信息传导、细胞骨架重排的调控,是细胞增殖、分化和运动的重要因素。目前认为,c-met与多种癌的发生和转移密切相关,研究表明,许多肿瘤病人...
First discovered over a decade ago, more than 100 different mutations resulting in exon 14 skipping have been described. These mutations occur in the sites at which splicing takes place during the processing of precursor messenger RNA (mRNA) into mature mRNA and, in the MET gene, the...
Kwon D, Koh J, Kim S, Go H, Kim YA, Keam B, et al. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics. Lung Cancer. 2017; 106: 131-7....
MET exon14 skipping mutation (METΔ14ex)Targeted therapyImmune checkpoint inhibitorThe cellular-mesenchymal to epithelial transition factor (MET) gene plays a crucial role in maintaining cell homeostasis, motility, and apoptosis. In cancer, MET gene alterations promote tumour cell proliferation, invasion ...
MET Exon 14 Skipping Mutation inNon-Small Cell Lung Cancer Identifiedby Anchored Multiplex PCR and Next-Generation SequencingTafe LJde Abreu FBPeterson JDTsongalis GJ
Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer. Recent studies revealed MET exon 14 skipping (METex14) as a biomarker that predicts the response to MET inhibitors in non-small-cell lung cancer (NSCLC). H... Eun,Kyung...
MET exon 14 skipping is one of the rare mutations in non-small cell lung cancer (NSCLC), involving its pathogenesis and progression. The performances of several MET inhibitors in clinical trials have been validated based on NGS, immunohistochemistry (IHC
MET exon 14 (METex14) skipping mutation has been defined as a unique genomic subtype of non-small cell lung cancer (NSCLC). The incidence of METex14 skipping alteration in NSCLC is approximately 3%–4%.1 Patients’ median age at diagnosis is 72–73 years old, which is significantly older ...
针对MET14号外显子跳跃突变,2021年国内外均有新药获批上市(赛沃替尼和Tepotinib);Amivantamab也初显疗效,值得期待。针对RET靶点,国内也迎来首个RET抑制剂普拉提尼。希望未来能够进一步加快少见或罕见靶点新药的研发和上市,给患者带来更多的治疗选择。 四、不限制突变类型:前景广阔,令人期待...
9036 Background: Exon 14 skipping mutations in the mesenchymal-epithelial transition ( MET) gene are reported in 2-5% of lung adenocarcinomas and are mutually exclusive of other driver mutations. Small-molecule MET tyrosine kinase inhibitors, capmatinib and tepotinib, showed durable responses in prev...